Drug overdose is the leading cause of unintentional death in the United States, and opioids are the most common cause of fatal overdoses. With the ability to stop an overdose in its tracks, naloxone is a lifesaving medication. Learn about the laws surrounding its use, the available naloxone products, and the logistics of dispensing take-home formulations.
After participating in this activity, the pharmacist will be able to:
- Describe validated tools and practice-based methods to assess the risk
foropioid-induced respiratory depression.
- Identify models for overdose education and naloxone distribution that are applicable to various practice settings.
- Describe strategies to overcome some of the barriers to implementing overdose education and naloxone distribution.
- Summarize and demonstrate essential patient/caregiver overdose education elements for community and health care settings.
- Explain evolving state laws regarding options for pharmacists to prescribe or dispense naloxone under collaborative practice agreements, protocols or standing orders.
Activity type: Application-based
Learning level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours of CPE credit (0.125 CEUs). The ACPE Universal Activity Numbers for this activity is 0202-0000-18-046-H01-P.
To obtain credit for "Naloxone: Understanding Its Role and Expanding its Access in Community Pharmacies," complete the assessment with a grade of 70% or better, evaluation questions, and CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: March 16, 2018
Expiration date: March 16,
"Naloxone: Understanding Its Role and Expanding its Access in Community Pharmacies” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
Anita Jacobson, PharmD declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.
Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements to have a positive learning experience.